IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$41.38 USD
+0.38 (0.93%)
Updated May 22, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
IDEAYA Biosciences, Inc. [IDYA]
Reports for Purchase
Showing records 21 - 40 ( 168 total )
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Pol Theta Inhibitor Cleared for Clinic; Playing Nice with PARPs
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Daro Data Delivers Solid Platform for the Platform
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Updated Clinical Data in Uveal Melanoma Impressive; Increasing PT to $35
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -AACR 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; IDYA Set for More Strides in the Clinic in 2023
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Notes from R&D Day; IDE161 Set for Broad Opportunity
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Busy Year Ahead with Four Clinical Candidates Expected in 1H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
mUM Update Supports 1L Path; Q1:23 Registration Study Initiation
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Reports of the Death of Synthetic Lethality are Grossly Exaggerated
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDE397 GSK Option Package Delivered; Collaboration with Amgens PRMT5i
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R